Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 27;11:5426. doi: 10.1038/s41467-020-19197-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — Perfusion of 1 µM Lovastatin (LS) with 50 μg/ml eLDL blocks eLDL-mediated altered vasoactivity (a–i) (mean ± S.D., n = 4 TEBVs, Phe: phenylephrine, Ach: acetylcholine) and NO production (a-ii) in TEBVs (mean ± S.D., n = 2 from 8 TEBVs, R means recovery). b Lovastatin (1 µM) blocks the 50 U/ml TNFα mediated dysfunction of vasoactivity (i, mean ± S.D., n = 3 TEBVs, Phe: phenylephrine, Ach: acetylcholine) and NO production in TEBVs (ii, mean ± S.D., n = 2 from 8 TEBVs, R means recovery). c Lovastatin block eLDL-mediated monocyte accumulation in TEBVs (mean ± S.D., n = 4,7,5,4,4 TEBVs by two-way ANOVA). d Lovastatin inhibits ICAM-1 and E-selectin expression on endothelial cells in TEBVs (mean ± S.D., n = 5,3,4,5,3 TEBVs for VCAM-1 accordingly, n = 4,3,4,5,4 TEBVs for ICAM-1 accordingly, n = 5,3,4,4,4 TEBVs for E-Selectin accordingly, **P = 0.0097, ***P = 0.0007 by two-way ANOVA and Tukey post hoc test, MFI = mean fluorescence intensity). e Lovastatin (LS) blocks primary monocyte differentiation into macrophages, flow cytometry testing of CD80 (mean ± S.D., n = 3 independent wells from one monocyte isolations, ICAM-1: **P = 0.00016, E-Selectin: ***P < 0.0001 by Student’s t test, MFI = mean fluorescence intensity). f Lovastatin (LS) blocks primary monocytes activation, flow cytometry testing of CD36 (mean ± S.D., n = 3 independent wells, ***P < 0.0001 by Student’s t test, MFI = mean fluorescence intensity). (Flow rate: 0.5 ml/min per TEBV (0.4 Pa) for vasoactivity testing and 0.125 ml/min (0.1 Pa) for monocyte accumulation).